VYNE Therapeutics Reports $3.6M Net Loss in Q1 2026, Prepares for Merger with Yarrow Bioscience

VYNE Therapeutics Inc. reported a net loss of $3.6 million for the first quarter of 2026, a significant reduction from the $8.6 million loss recorded in the same period of 2025. The company's total revenues for the quarter were $86,000, primarily derived from royalty revenues, which decreased by 57.4% compared to $202,000 in the previous year. This decline in revenue is attributed to the company's ongoing transition and strategic focus, particularly following the termination of its Phase 1b trial for VYN202 and the winding down of research and development activities in anticipation of a merger with Yarrow Bioscience.

Operating expenses for VYNE decreased to $3.9 million in the first quarter of 2026, down 58.5% from $9.4 million in the same quarter of 2025. This reduction was largely driven by a significant decrease in research and development expenses, which fell to $817,000 from $6.1 million, reflecting the company's strategic decision to halt certain clinical trials and focus on the merger. General and administrative expenses remained relatively stable, totaling $3.1 million, compared to $3.3 million in the prior year.

In terms of strategic developments, VYNE is in the process of merging with Yarrow Bioscience, a transaction expected to close in the third quarter of 2026, pending stockholder and regulatory approvals. This merger is anticipated to shift VYNE's primary business focus to Yarrow's clinical-stage monoclonal antibody targeting the thyroid-stimulating hormone receptor. The merger agreement includes a pre-closing financing commitment of approximately $100 million, which is expected to bolster VYNE's financial position post-merger.

As of March 31, 2026, VYNE had cash, cash equivalents, and marketable securities totaling $24.9 million, with no outstanding debt. The company has indicated that its existing resources are sufficient to fund operations through the anticipated merger closing and for at least 12 months thereafter. However, VYNE has acknowledged the need for additional capital to support future product development, particularly if the merger does not proceed as planned. The company is also preparing to declare a special cash dividend of approximately $14.5 million to $16.5 million to its stockholders prior to the merger.

Looking ahead, VYNE's future operations are heavily reliant on the successful completion of the merger with Yarrow. The company has suspended its research and development activities and is evaluating strategic alternatives for its existing product candidates. The ongoing macroeconomic conditions, including inflation and market volatility, present additional challenges that could impact VYNE's financial performance and operational capabilities in the near term.